Biomed_PRESOL_mg2_18_tmFINAL_2.pdf

Pre-solicitation Notice

THIS IS NOT A REQUEST FOR PROPOSALS (RFP). THIS IS A PRE-SOLICITATION

ANNOUNCEMENT ONLY. AN RFP WILL BE ISSUED VIA SAM.GOV ON OR ABOUT MAY

4, 2022. THE ANTICIPATED DUE DATE FOR SUBMISSION OF PROPOSALS IN

RESPONSE TO THE RFP IS ON OR ABOUT JUNE 24, 2022.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Division of Population Health Research (DIPHR) is planning to issue an RFP for a single award Indefinite Delivery, Indefinite Quantity (IDIQ) type contract for an ordering period of ten (10) years for the Biomedical Assay Laboratory for the DIPHR.

The goal of the contract is to conduct research on a variety of topics pertaining to human reproduction and development, child and adolescent health and behavior, and care of pregnant women, among other topics. Both observational and interventional research studies are designed and implemented by DiPHR scientists, and most research includes collection of a diverse array of data and biospecimens.

This effort is for laboratory analysis services to measure the concentrations of a vast number of biomarkers from an array of biospecimens. All biospecimens are collected using approved protocols and are de-identified prior to storage in NICHD-supported repositories.

The contractor shall receive no identifying or personal health information about the study subjects. A wide range of specimen types are collected including whole blood, cord blood, buffy coats, plasma, serum, urine, saliva, tissues (e.g., placenta, omental fat), hair, nail clippings, follicular and seminal fluid, semen, rectal swabs, and newborn blood spots.

a) DiPHR requires analysis of this diverse collection of specimen types for a multitude of factors, including measurement of inflammatory markers (e.g., isoprostanes, leukotrienes)

b) DNA extraction from whole blood

c) DNA extraction from pre-washed newborn blood spots

d) DHEA, DHEAS, and cortisol

e) Female and male reproductive hormones including estrogen, progesterone, luteinizing hormone, follicle-stimulating hormone, testosterone, serum hormone binding globulin, inhibin-B, estradiol, anti-mullerian hormone, and gluconated metabolites of the above where appropriate

f) C-reactive protein

g) Markers of angiogenesis including soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor, and soluble edoglin

h) Markers of adipogenesis, lipolysis, and lipogenesis including lipid and fatty acid profiles, C1q/TNF-related proteins (CTRPs 1, 3, 5, 6, 7, 9, and 15), adiponectin, high molecular weight adiponectin, leptin, soluble leptin receptor, vaspin, omentin-1, triglycerides, HDL, LDL, VLDL, and total cholesterol

i) Measurements of glucose metabolism including HbA1c, C-peptide, insulin, and glucose

j) Measurements of renal function including creatinine, urea nitrogen, cystatin C, and the urine albumin to creatinine ratio (ACR).

k) Antioxidants, including ascorbic acid, tocopherols, and carotenoids.

l) Measurement of thyroid function including thyroid stimulating hormone, triiodothyronine free (FT3), thyroxine free (FT4), and thyroid peroxidase antibodies (TPO-Ab).

m) Pro- and anti-inflammatory cytokines

n) Vitamins including 25-(OH) Vitamin D2 and D3, Vitamin B6 and B12

o) Other biomarkers including ferritin, transferrin receptor, hepcidin, insulin-like growth factor and binding proteins, uric acid, F2 isoprostanes, acylcarnities, and amino acids

p) LC/MS measurement of caffeine, theobromine, and paraxanthine

q) Quantification of semen parameters including but not limited to motility, morphology, and DNA fragmentation

It is anticipated that a cost-reimbursement IDIQ contract will be awarded, for a period of performance of 10 years, beginning approximately September 17, 2022. The RFP is anticipated to be posted on or about May 4, 2022, and may be accessed through the sam.gov website at sam.gov. The due date for submission of proposals in response to the RFP is anticipated to be on or about June 24, 2022. Information in the anticipated RFP supersedes any information in this pre-solicitation announcement. This acquisition is a full and open competition under the North American Industry Classification System (NAICS) code 541715. Any questions concerning this announcement must be submitted by email to the following two Contracting Officers: Megan Gnall, megan.gnall@nih.gov, and Ty Main, ty.main@nih.gov Emails must reference the announcement number in the subject line.

This is not an RFP, and this announcement does not commit the Government to award a contract. The reference number to be used for this announcement is 75N94022R00006.

All correspondence must cite the reference number as provided.

mailto:megan.gnall@nih.gov mailto:ty.main@nih.gov